SCH 28080对人体胃分泌抑制作用的研究。
A study of the inhibitory effects of SCH 28080 on gastric secretion in man.
作者信息
Ene M D, Khan-Daneshmend T, Roberts C J
出版信息
Br J Pharmacol. 1982 Jul;76(3):389-91. doi: 10.1111/j.1476-5381.1982.tb09232.x.
Abstract
1 SCH 28080 (2-methyl-8-(phenyl methoxy) imidazo-(1-2-a) pyrine-3-acetonitrile) is a novel drug unrelated to existing anti-ulcer agents. 2 The effect of placebo and increasing doses of the drug on gastric acid output and peptic activity was examined in four healthy men, in the resting state and following pentagastrin stimulation. 3 Significant inhibition of gastric acid secretion and peptic activity occurred with the 50 mg dose in both the stimulated and unstimulated states. Approximately 90% inhibition of acid output was achieved with the 200 mg dose. 4 Antisecretory activity of SCH 28080 is confirmed in man. This drug or an analogue may have potential in anti-ulcer therapy.
摘要
- SCH 28080（2-甲基-8-（苯甲氧基）咪唑并[1,2-a]吡啶-3-乙腈）是一种与现有抗溃疡药物无关的新型药物。2. 在四名健康男性中，研究了安慰剂和递增剂量的该药物在静息状态下以及五肽胃泌素刺激后的胃酸分泌量和胃蛋白酶活性。3. 在刺激和未刺激状态下，50毫克剂量的药物均能显著抑制胃酸分泌和胃蛋白酶活性。200毫克剂量可实现约90%的胃酸分泌抑制。4. SCH 28080的抗分泌活性在人体中得到证实。这种药物或其类似物在抗溃疡治疗中可能具有潜力。
相似文献
1
A study of the inhibitory effects of SCH 28080 on gastric secretion in man.SCH 28080对人体胃分泌抑制作用的研究。
Br J Pharmacol. 1982 Jul;76(3):389-91. doi: 10.1111/j.1476-5381.1982.tb09232.x.
2
Antisecretory activity of pirenzepine versus cimetidine in man: a controlled study.哌仑西平与人用西咪替丁抗分泌活性的对照研究。
Gut. 1984 Feb;25(2):178-82. doi: 10.1136/gut.25.2.178.
3
Gastric antisecretory and cytoprotective activities of SCH 28080.SCH 28080的胃抗分泌及细胞保护活性
J Pharmacol Exp Ther. 1983 Jul;226(1):114-20.
4
Effects of SCH 32651 on resting and stimulated acid secretion in guinea-pig isolated fundic mucosa.SCH 32651对豚鼠离体胃底黏膜静息和刺激状态下胃酸分泌的影响。
Br J Pharmacol. 1984 Sep;83(1):75-82. doi: 10.1111/j.1476-5381.1984.tb10121.x.
5
Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man.单次及重复剂量奥美拉唑对人体胃酸和胃蛋白酶分泌的影响。
Gut. 1984 Jul;25(7):707-10. doi: 10.1136/gut.25.7.707.
6
Gastric antisecretory properties of SCH 32651.SCH 32651的胃抗分泌特性。
Arch Int Pharmacodyn Ther. 1984 Jul;270(1):116-27.
7
Increased effect of multiple doses of 40 749 RP a new long acting gastric antisecretory agent.新型长效胃泌素分泌抑制剂40 749 RP多次给药后效果增强。
Eur J Clin Pharmacol. 1986;30(3):269-71. doi: 10.1007/BF00541526.
8
Studies on the mechanisms of the antisecretory and cytoprotective actions of SCH 28080.SCH 28080的抗分泌及细胞保护作用机制研究。
J Pharmacol Exp Ther. 1983 Jul;226(1):121-5.
9
10
Effects of Helicobacter pylori on gastritis, pentagastrin-stimulated gastric acid secretion, and meal-stimulated plasma gastrin release in the absence of peptic ulcer disease.在无消化性溃疡病的情况下，幽门螺杆菌对胃炎、五肽胃泌素刺激的胃酸分泌及进餐刺激的血浆胃泌素释放的影响。
Am J Gastroenterol. 1998 Aug;93(8):1277-85. doi: 10.1111/j.1572-0241.1998.409_x.x.
引用本文的文献
1
[History and Pharmacological Mechanism of Gastric Acid-suppressive Drugs].[胃酸抑制药物的历史与药理机制]
Korean J Helicobacter Up Gastrointest Res. 2023 Sep;23(3):159-166. doi: 10.7704/kjhugr.2023.0040. Epub 2023 Sep 8.
2
Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System.钾离子竞争性酸阻滞剂与质子泵抑制剂治疗胃溃疡的疗效：通过质量管理体系进行交叉推断的贝叶斯和频率学派网络荟萃分析
Curr Ther Res Clin Exp. 2025 Feb 5;102:100776. doi: 10.1016/j.curtheres.2025.100776. eCollection 2025.
3
A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (X842) and Lansoprazole for the Treatment of Patients With Erosive Esophagitis.一项关于钾离子竞争性酸阻滞剂（X842）与兰索拉唑治疗糜烂性食管炎患者的随机对照试验。
Clin Transl Gastroenterol. 2025 Apr 1;16(4):e00803. doi: 10.14309/ctg.0000000000000803.
4
Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology.胃酸分泌的神经内分泌机制：生理学和药理学的历史观点和最新进展。
J Neuroendocrinol. 2023 Nov;35(11):e13305. doi: 10.1111/jne.13305. Epub 2023 Jun 15.
5
Potassium-competitive acid blockers and gastroesophageal reflux disease.钾离子竞争型酸阻断剂与胃食管反流病。
World J Gastroenterol. 2022 Jul 28;28(28):3608-3619. doi: 10.3748/wjg.v28.i28.3608.
6
The role of vonoprazan in patients with erosive esophagitis.沃克帕唑在糜烂性食管炎患者中的作用。
Therap Adv Gastroenterol. 2022 Sep 13;15:17562848221122623. doi: 10.1177/17562848221122623. eCollection 2022.
7
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.富马酸沃克索拉唑，一种新型钾离子竞争性酸阻滞剂，用于治疗胃食管反流病：迄今为止的安全性和临床证据。
Therap Adv Gastroenterol. 2018 Jan 9;11:1756283X17745776. doi: 10.1177/1756283X17745776. eCollection 2018.
8
Potassium Channelopathies and Gastrointestinal Ulceration.钾通道病与胃肠道溃疡
Gut Liver. 2016 Nov 15;10(6):881-889. doi: 10.5009/gnl15414.
9
The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.沃克帕唑（TAK-438）对胃H⁺，K⁺ -ATP酶的结合选择性。
Aliment Pharmacol Ther. 2015 Dec;42(11-12):1315-26. doi: 10.1111/apt.13414. Epub 2015 Sep 30.
10
Role of potassium in acid secretion.钾在胃酸分泌中的作用。
World J Gastroenterol. 2005 Sep 14;11(34):5259-65. doi: 10.3748/wjg.v11.i34.5259.
本文引用的文献
1
The effect of ranitidine and cimetidine on pentagastrin and insulin stimulated gastric secretion.雷尼替丁和西咪替丁对五肽胃泌素和胰岛素刺激的胃分泌的影响。
Scand J Gastroenterol Suppl. 1981 Jun;69:51-9.
2
A modified hemoglobin substrate method for the estimation of pepsin in gastric juice.一种改良的血红蛋白底物法用于测定胃液中的胃蛋白酶。
Scand J Gastroenterol. 1970;5(5):343-8.
3
Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins.前列腺素的抗分泌、抗溃疡、细胞保护及致泻特性。
Adv Prostaglandin Thromboxane Res. 1976;2:507-20.
4
Cerebral blood-flow in polycythaemia.真性红细胞增多症中的脑血流量
Lancet. 1977 Jul 23;2(8030):161-3. doi: 10.1016/s0140-6736(77)90179-9.
Zotero 插件